Model-Informed Precision Dosing Guidance of Ethosuximide Developed from a Randomized Controlled Clinical Trial of Childhood Absence Epilepsy.
Mizuno K, Capparelli EV, Fukuda T, Dong M, Adamson PC, Blumer JL, Cnaan A, Clark PO, Reed MD, Shinnar S, Vinks AA, Glauser TA; Childhood Absence Epilepsy Study Group.
Mizuno K, et al. Among authors: blumer jl.
Clin Pharmacol Ther. 2023 Aug;114(2):459-469. doi: 10.1002/cpt.2965. Epub 2023 Jun 25.
Clin Pharmacol Ther. 2023.
PMID: 37316457
Clinical Trial.
However, 47% of ethosuximide initial monotherapy participants experienced short-term treatment failure. This study aimed to characterize the initial monotherapy ethosuximide exposure-response relationship and to propose model-informed precision dosing guidance. ...
However, 47% of ethosuximide initial monotherapy participants experienced short-term treatment failure. This study aimed to character …